## **Amendments to the Claims:**

This listing of clams will replace all prior versions, and listings, of claims in the application:

## **Listing of Claims**

Claim 1. (Previously Presented) A compound of the formula I:

$$R^1$$
 $O$ 
 $R^2$ 
 $HN$ 
 $R^3$ 
 $I$ 

wherein:

 $R^1$  is  $R^4$ -S(O)<sub>D</sub>N( $R^5$ )-,

wherein R<sup>4</sup> is independently selected from the group consisting of:

- -C<sub>1-8</sub>alkyl, which is unsubstituted or substituted with 1-6 fluoro, (a)
- -NR5R6, (b)
- (c) phenyl, and
- (d) benzyl,

wherein R<sup>5</sup> and R<sup>6</sup> are independently selected from the group consisting of:

- hydrogen, (a)
- -C<sub>1-6</sub>alkyl, which is unsubstituted or substituted with 1-6 fluoro, (b)
- (c) phenyl, and
- benzyl, (d)

and wherein p is independently 0, 1, or 2;

## R<sup>2</sup> is selected from the group consisting of:

- hydrogen, (1)
- -C<sub>1</sub>-6alkyl, -C<sub>2</sub>-6alkenyl, -C<sub>2</sub>-6alkynyl, or -C<sub>3</sub>-8cycloalkyl which is unsubstituted or (2) substituted with 1-7 substituents where the substituents are independently selected from:
  - (a) halo,
  - (b) hydroxy,
  - (c) -O-C<sub>1-6</sub>alkyl,
  - (d) -C3-6cycloalkyl,
  - $-S(O)_p-C_{1-6}$ alkyl, (e)
  - (f) -CN,
  - -CO<sub>2</sub>H, (g)
  - -CO<sub>2</sub>-C<sub>1</sub>-6alkyl, (h)
  - -CO-NR<sup>5</sup>R<sup>6</sup>, (i)
  - phenyl, which is unsubstituted or substituted with 1-5 substituents where the (j) substituents are independently selected from:
    - (i) -C<sub>1-6</sub>alkyl,
    - (ii) -CN,
    - (iii) halo,
    - -CF<sub>3</sub>, (iv)
    - -O-R<sup>5</sup>, and (v)
    - $-CO_2R^5$ , (vi)
- phenyl which is unsubstituted or substituted with 1-5 substituents where the substituents are (3) independently selected from:
  - (a) - $C_{1-6}$ alkyl,
  - -CN, (b)
  - (c) halo,
  - (d)  $-CF_3$ ,
  - -O-R<sup>5</sup>, and (e)
  - $-CO_2R^5$ ; (f)

R<sup>3</sup> is selected from the group consisting of:

(1) hydrogen,

(2) -C<sub>1</sub>-6alkyl, -C<sub>2</sub>-6alkenyl, -C<sub>2</sub>-6alkynyl, or -C<sub>3</sub>-8cycloalkyl which is unsubstituted or substituted with 1-7 substituents where the substituents are independently selected from:

- (a) halo,
- (b) hydroxy,
- (c) -O-C<sub>1-6</sub>alkyl,
- -C3-6cycloalkyl, (d)
- (e) phenyl or pyridyl, which is unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from:
  - (i) -C<sub>1</sub>-6alkyl,
  - (ii) -CN,
  - (iii) halo,
  - -CF<sub>3</sub>, (iv)
  - -O-R<sup>5</sup>, and (v)
  - $-CO_2R^5$ , (vi)
- $-S(O)_pN(R^5)-C_{1-6}$ alkyl, and (f)
- $-S(O)_pN(R^5)$  phenyl, (g)
- (3) phenyl which is unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from:
  - (a) -C<sub>1</sub>-6alkyl,
  - (b) -CN,
  - (c) halo,
  - -CF<sub>3</sub>, (d)
  - -O-R<sup>5</sup>, and (e)
  - $-CO_2R^5$ ; (f)

X is selected from the group consisting of:

- -CH<sub>2</sub>-, and (1)
- (2) -O-;

and pharmaceutically acceptable salts thereof.

Claim 2 (Original) The compound of Claim 1 of the formula II:

II.

Claim 3 (Original) The compound of Claim 2 wherein:

R1 is selected from:

- CH3-S(O)2N(CH3)-; (1)
- CH3CH2-S(O)2N(CH3)-; (2)
- (CH<sub>3</sub>)<sub>2</sub>CH-S(O)<sub>2</sub>N(CH<sub>3</sub>)-; (3)
- phenyl-S(O)2N(CH3)-; and (4)
- (CH<sub>3</sub>)<sub>2</sub>N-S(O)<sub>2</sub>N(CH<sub>3</sub>)-; (5)

R<sup>2</sup> is -C<sub>1-6</sub>alkyl, unsubstituted or substituted with cyclopropyl or halo;

R<sup>3</sup> is -C<sub>1-6</sub>alkyl or -C<sub>3-8</sub>cycloalkyl; and

X is -CH2- or -O-;

and pharmaceutically acceptable salts thereof.

Claim 4 (Original) The compound of Claim 1 of the formula III:

Serial No.: 10/568,153 Case No.: 21504YP

Page No.: 6

III.

Claim 5 (Original) The compound of Claim 1 wherein:

R<sup>1</sup> is selected from:

- (1)  $CH_3-S(O)_2N(CH_3)-;$
- (2)  $CH_3CH_2-S(O)_2N(CH_3)-;$
- (3)  $(CH_3)_2CH-S(O)_2N(CH_3)_{-}$ ;
- (4) phenyl-S(O)<sub>2</sub>N(CH<sub>3</sub>)-; and
- (5)  $(CH_3)_2N-S(O)_2N(CH_3)-;$

 $R^2$  is -C<sub>1-6</sub>alkyl, unsubstituted or substituted with cyclopropyl or halo;

R<sup>3</sup> is -C<sub>1-6</sub>alkyl or -C<sub>3-8</sub>cycloalkyl; and

X is -CH<sub>2</sub>- or -O-;

and pharmaceutically acceptable salts thereof.

Claim 6 (Original) The compound of Claim 1 wherein:

 $R^1$  is  $R^4$ -S(O)2N( $R^5$ )-,

wherein R<sup>4</sup> is independently selected from the group consisting of:

- (a) -C<sub>1-6</sub>alkyl, which is unsubstituted or substituted with 1-6 fluoro,
- (b) phenyl, and
- (c) benzyl,

and wherein R<sup>5</sup> is independently selected from the group consisting of:

- (a) hydrogen,
- (b) -C<sub>1-6</sub>alkyl, which is unsubstituted or substituted with 1-6 fluoro,
- (c) phenyl, and

## (d) benzyl.

Claim 7 (Original) The compound of Claim 6 wherein R<sup>1</sup> is selected from:

- CH3-S(O)2N(CH3)-; (1)
- (2) CH3CH2-S(O)2N(CH3)-;
- (CH<sub>3</sub>)<sub>2</sub>CH-S(O)<sub>2</sub>N(CH<sub>3</sub>)-; and (3)
- (4) phenyl-S(O)<sub>2</sub>N(CH<sub>3</sub>)-;
- (CH<sub>3</sub>)<sub>2</sub>N-S(O)<sub>2</sub>N(CH<sub>3</sub>)-. (5)

Claim 8 (Original) The compound of Claim 7 wherein R<sup>1</sup> is CH<sub>3</sub>-S(O)<sub>2</sub>N(CH<sub>3</sub>)-.

Claim 9 (Original) The compound of Claim 1 wherein R<sup>2</sup> is -C<sub>1</sub>-6alkyl, unsubstituted or substituted with cyclopropyl or halo.

Claim 10 (Original) The compound of Claim 9 wherein R<sup>2</sup> is selected from:

- (1) CH3-;
- CH<sub>3</sub>CH<sub>2</sub>-; (2)
- (3) (CH<sub>3</sub>)<sub>2</sub>CH-;
- CH<sub>3</sub>CH<sub>2</sub>CH<sub>2</sub>-; (4)
- (5) (CH<sub>3</sub>)<sub>2</sub>CHCH<sub>2</sub>-;
- CH3CH2CH2CH2-; (6)
- CH3CH2CH2CH2CH2-; (7)
- (8) cyclopropyl-CH2-;
- (9) CF3CH2-; and
- (10)CH<sub>2</sub>FCH<sub>2</sub>-.

Claim 11 (Original) The compound of Claim 1 wherein R<sup>3</sup> is -C<sub>1</sub>-6alkyl or -C<sub>3</sub>-8cycloalkyl.

Claim 12 (Original) The compound of Claim 11 wherein R<sup>3</sup> is selected from:

- (1) CH3-;
- (2) CH<sub>3</sub>CH<sub>2</sub>-;
- (CH<sub>3</sub>)<sub>2</sub>CH-; (3)
- CH<sub>3</sub>CH<sub>2</sub>CH<sub>2</sub>-; (4)

(5) (CH<sub>3</sub>)<sub>2</sub>CHCH<sub>2</sub>-;

- (6) CH<sub>3</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>-;
- (7) CH3CH2CH2CH2CH2-; and
- (8) bicyclo[2.2.1]heptyl-.

Claim 13 (Original) The compound of Claim 12 wherein R<sup>3</sup> is (CH<sub>3</sub>)<sub>2</sub>CHCH<sub>2</sub>-.

Claim 14 (Previously Presented) A compound of Claim 1 which is selected from the group consisting of:

Ex	Structure	Ex	Structure
2		3	
4	O N H H H H N O	5	

Ex	Structure	Ex	Structure
6	O N H H N H O	7	
8	O N N N N N N N N N N N N N N N N N N N	9	ON NH ON HANDER OF THE PART OF
10	O S N H N H N H N	11	

Ex	Structure	Ex	Structure
12	O S P T T T T T T T T T T T T T T T T T T	13	
14		15	
16	O S N HN N H O O	17	O S O T T T T T T T T T T T T T T T T T

Ex	Structure	Ex	Structure
18	OS N HN NH O	19	O S N HN HN O
20	OS N H N H N O	21	O S N N N N N N N N N N N N N N N N N N
22		23	

Ex	Structure	Ex	Structure
24	ON O	25	O Z HZ O HZ O
26	ON NH NH O		
28		29	ON ON THE STATE OF

Ex	Structure	Ex	Structure
30		31	
32		33	
34		35	

Ex	Structure	Ex	Structure
36		37	

and pharmaceutically acceptable salts thereof.

Claim 15 (Original) A pharmaceutical composition comprising an effective amount of a compound of Claim 1 and a pharmaceutically acceptable carrier.

Claim 16 (Canceled)

Claim 17 (Canceled)

Claim 18 (New) A compound of Claim 1 which is

or a pharmaceutically acceptable salt thereof.